BridgeBio Pharma Other Non-Current Liabilities 2018-2024 | BBIO

BridgeBio Pharma other non-current liabilities for the quarter ending December 31, 2024 were $0.479B, a 8408.64% increase year-over-year.

  • BridgeBio Pharma other non-current liabilities for 2024 were $0.479B, a 8408.64% increase from 2023.
  • BridgeBio Pharma other non-current liabilities for 2023 were $0.006B, a 78.85% decline from 2022.
  • BridgeBio Pharma other non-current liabilities for 2022 were $0.027B, a 20.73% increase from 2021.

BridgeBio Pharma Other Non-Current Liabilities 2018-2024 | BBIO

  • BridgeBio Pharma other non-current liabilities for 2024 were $0.479B, a 8408.64% increase from 2023.
  • BridgeBio Pharma other non-current liabilities for 2023 were $0.006B, a 78.85% decline from 2022.
  • BridgeBio Pharma other non-current liabilities for 2022 were $0.027B, a 20.73% increase from 2021.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$19.4B
Dr Reddy's Laboratories (RDY)$11.2B
Bausch Health Cos (BHC)$2.4B
Supernus Pharmaceuticals (SUPN)$1.9B
Amphastar Pharmaceuticals (AMPH)$1.5B
Personalis (PSNL)$412M
Taysha Gene Therapies (TSHA)$336M
Assembly Biosciences (ASMB)$81M
Sol-Gel Technologies (SLGL)$16M
Evoke Pharma (EVOK)$8M
Teligent (TLGT)$0M